Cargando…

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients

Detalles Bibliográficos
Autores principales:	Davidov, Yana, Indenbaum, Victoria, Mandelboim, Michal, Asraf, Keren, Gonen, Tal, Tsaraf, Keren, Cohen-Ezra, Oranit, Likhter, Mariya, Yaacov, Gil Ben, Nemet, Ital, Kliker, Limor, Mor, Orna, Doolman, Ram, Cohen, Carmit, Afek, Arnon, Kreiss, Yitshak, Regev, Gili, Lustig, Yaniv, Ari, Ziv Ben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	POSTER PRESENTATIONS: Saturday 25 June: Liver transplantation and hepatobiliary surgery: Clinical aspects
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252410/ http://dx.doi.org/10.1016/S0168-8278(22)01913-4

Ejemplares similares

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
por: Regev-Yochay, Gili, et al.
Publicado: (2022)

A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
por: Gilboa, Mayan, et al.
Publicado: (2022)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant
por: Peled, Yael, et al.
Publicado: (2022)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study
por: Joseph, Gili, et al.
Publicado: (2023)

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
por: Lustig, Yaniv, et al.
Publicado: (2021)

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
por: Barda, Noam, et al.
Publicado: (2023)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2023)

Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022–2023 Winter Season
por: Moss, Stephen, et al.
Publicado: (2023)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Liver transplant patients infection rate with SARS-CoV-2 is lower but depend upon the infection rate in the general population and have a better outcome
por: Cohen-Naftaly, Michal, et al.
Publicado: (2022)

The Rise and Fall of a Local SARS-CoV-2 Variant with the Spike Protein Mutation L452R
por: Mor, Orna, et al.
Publicado: (2021)

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
por: Lustig, Yaniv, et al.
Publicado: (2021)

Sustainability of humoral immunity induced by the SARS-CoV-2 vaccine and response to booster dose among Liver Transplant recipients
por: Rabinowich, Liane, et al.
Publicado: (2022)

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021)

Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy
por: Nir, Omer, et al.
Publicado: (2022)

TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
por: Lawitz, Eric, et al.
Publicado: (2022)

P203 Earlier identification of human immunodeficiency virus and hepatitis C virus in high-risk emergency departments
por: Fenton, J., et al.
Publicado: (2009)

The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial
por: Biber, Asaf, et al.
Publicado: (2022)

Synovial C-Shaped Tibial Footprint of the Anterior Cruciate Ligament
por: Janovsky, César, et al.
Publicado: (2016)

Outbreak of Influenza and Other Respiratory Viruses in Hospitalized Patients Alongside the SARS-CoV-2 Pandemic
por: Fratty, Ilana S., et al.
Publicado: (2022)

Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine
por: Schwartz, Anat, et al.
Publicado: (2021)

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022
por: Kliker, Limor, et al.
Publicado: (2022)

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
por: Bergwerk, Moriah, et al.
Publicado: (2021)

Cocirculation of A(H3N2) and B/Victoria increased morbidity in hospitalized patients in the 2019–2020 A(H1N1)pdm09 predominant influenza season in Israel
por: Jurkowicz, Menucha, et al.
Publicado: (2023)

Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study
por: Regev-Yochay, Gili, et al.
Publicado: (2023)

SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine
por: Raszeja-Wyszomirska, Joanna, et al.
Publicado: (2022)

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients
por: Guarino, Maria, et al.
Publicado: (2022)

The impact of COVID-19 on the duration of the liver transplant process in patients presenting for inpatient liver transplant evaluation
por: Cooper, Katherine, et al.
Publicado: (2022)

Impact of COVID-19 on the liver transplant activity in the US: variation by the region, etiology, and cirrhosis complications
por: Singal, Ashwani, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Long-lasting seropositivity after anti SARS-CoV-2 vaccination in pre liver transplant patients
por: Calleri, Alberto, et al.
Publicado: (2022)

SARS-CoV-2 infection in liver transplant recipients-a single center case series from Romania
por: Husar-Sburlan, Ioana-Alexandra, et al.
Publicado: (2022)

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in liver transplant recipients
por: Herrán, Aitor Odriozola, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4hr95ia91kuasnic21kjibpl80